Perspective Therapeutics announces leadership participation in investor conferences, showcasing cancer treatment advancements and proprietary radiopharmaceutical technology.
Quiver AI Summary
Perspective Therapeutics, Inc., a radiopharmaceutical development company focused on advanced cancer treatments, announced that its senior leadership team will engage with investors at two upcoming healthcare conferences. These include a fireside chat at the Piper Sandler & Co. 37th Annual Healthcare Conference in New York on December 2, 2025, and another at the Evercore 8th Annual Healthcare Conference in Miami on December 3, 2025. The company utilizes proprietary technology with the alpha-emitting isotope 212Pb to target cancer cells, and is developing complementary imaging diagnostics to personalize treatment. Perspective’s programs for neuroendocrine tumors, melanoma, and solid tumors are currently in Phase 1/2a clinical trials. The company is also expanding its facilities to ensure the delivery of drug product candidates for clinical and commercial use.
Potential Positives
- Participation in prominent healthcare conferences provides visibility and engagement opportunities with potential investors, enhancing the company's market presence.
- Development of innovative radiopharmaceuticals with a "theranostic" approach positions the company at the forefront of personalized cancer treatment, potentially improving patient outcomes.
- The company's Phase 1/2a trials for its neuroendocrine tumor, melanoma, and solid tumor programs indicate progress in its drug development pipeline, showcasing its commitment to advancing cancer therapies.
- Expansion of regional finishing facilities, supported by proprietary technology, enhances the company’s capacity to deliver patient-ready products for clinical trials and commercial operations.
Potential Negatives
- The press release heavily relies on forward-looking statements, which may draw skepticism from investors about the company's actual capabilities and future performance.
- The acknowledgment of risks and uncertainties associated with the company's projections could deter potential investors from engaging with the company.
- There is no mention of significant milestones or achievements that would demonstrate the company's progress, leading to potential concerns about its operational effectiveness.
FAQ
What is Perspective Therapeutics, Inc. known for?
Perspective Therapeutics is known for pioneering advanced radiopharmaceutical treatments for various cancers throughout the body.
When are the upcoming investor conferences for Perspective Therapeutics?
The upcoming investor conferences are on December 2, 2025, and December 3, 2025, in New York and Miami respectively.
What unique technology does Perspective Therapeutics use for cancer treatment?
The Company utilizes the alpha-emitting isotope 212Pb to deliver radiation specifically to cancer cells using specialized targeting moieties.
What is the "theranostic" approach in cancer treatment?
The "theranostic" approach allows for personalizing treatment by imaging tumors and then targeting them for effective radiation therapy.
Where can I find more information about Perspective Therapeutics?
More information can be found on Perspective Therapeutics' official website at www.perspectivetherapeutics.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CATX Insider Trading Activity
$CATX insiders have traded $CATX stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CATX stock by insiders over the last 6 months:
- JONATHAN ROBERT HUNT (Chief Accounting Officer) purchased 11,000 shares for an estimated $22,294
- ROBERT F III WILLIAMSON purchased 9,498 shares for an estimated $19,945
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CATX Hedge Fund Activity
We have seen 44 institutional investors add shares of $CATX stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCTAGON CAPITAL ADVISORS LP removed 3,018,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,381,920
- MORGAN STANLEY added 1,137,473 shares (+70.1%) to their portfolio in Q3 2025, for an estimated $3,901,532
- AVIDITY PARTNERS MANAGEMENT LP added 1,135,437 shares (+61.1%) to their portfolio in Q3 2025, for an estimated $3,894,548
- FMR LLC removed 1,091,905 shares (-9.8%) from their portfolio in Q3 2025, for an estimated $3,745,234
- NUVEEN, LLC removed 988,672 shares (-43.0%) from their portfolio in Q3 2025, for an estimated $3,391,144
- AFFINITY ASSET ADVISORS, LLC removed 750,000 shares (-71.4%) from their portfolio in Q3 2025, for an estimated $2,572,500
- MARSHALL WACE, LLP removed 520,707 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,786,025
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CATX Analyst Ratings
Wall Street analysts have issued reports on $CATX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 11/18/2025
- BTIG issued a "Buy" rating on 10/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/03/2025
- Wedbush issued a "Outperform" rating on 06/23/2025
- RBC Capital issued a "Outperform" rating on 06/03/2025
To track analyst ratings and price targets for $CATX, check out Quiver Quantitative's $CATX forecast page.
$CATX Price Targets
Multiple analysts have issued price targets for $CATX recently. We have seen 5 analysts offer price targets for $CATX in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Yuan Zhi from B. Riley Securities set a target price of $11.0 on 11/18/2025
- Jeet Mukherjee from BTIG set a target price of $14.0 on 10/13/2025
- Robert Burns from HC Wainwright & Co. set a target price of $10.0 on 10/03/2025
- David Nierengarten from Wedbush set a target price of $11.0 on 06/23/2025
- Leonid Timashev from RBC Capital set a target price of $16.0 on 06/03/2025
Full Release
SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:
Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside Chat
Date:
Tuesday, December 2, 2025
Time:
1:00 - 1:25 p.m. ET
Location
: New York, NY
Evercore 8th Annual Healthcare Conference – Fireside Chat
Date:
Wednesday, December 3, 2025
Time:
3:00 - 3:20 p.m. ET
Location:
Miami, FL
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com .
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company’s prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
[email protected]
Russo Partners, LLC
Nic Johnson
[email protected]
